Drug intelligence / Profile preview

4-1BB CTL

Development stage: Unknown
Lead developer: Eutilex
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

4-1BB CTL is an adoptive T-cell therapy, likely a Chimeric Antigen Receptor (CAR-T) cell therapy, developed by Eutilex. It is designed to target human telomerase reverse transcriptase (hTERT) on cancer cells. The therapy incorporates the 4-1BB (CD137) co-stimulatory domain, which is crucial for enhancing the proliferation, survival, and effector function of the T cells, thereby boosting anti-tumor immunity. This therapeutic approach aims to leverage the immune system to combat advanced refractory solid tumors.

Targets

TNFRSF9 (CD137 extracellular domain)

Beyond the preview

Go deeper on 4-1BB CTL.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 4-1BB CTL.

Explore the full profile